BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC
Fierce Pharma reports: BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC.
BioNTech is a public biotechnology company developing mRNA-based medicines, cancer immunotherapies, infectious-disease vaccines, and antibody-based oncology programs.
Company Info
Recent News
Fierce Pharma reports: BioNTech lays commercial groundwork for PD-L1xVEGF via HER2 ADC.
Leadership Team
Chief Executive Officer
Chief Medical Officer
Chief Financial Officer
Careers & Job Openings